Treatment of murine cancer models with inhibitory CCL2 antibodies controlled tumor progression; however, once treatment was discontinued, the survival rate of mice declined, highlighting the potential of drugs targeting CCL2 in the treatment of solid tumors [111]. Here, CCL2 is linked to cancer.